New drug targets 'Undruggable' cancer mutation in major trial
NCT ID NCT05005234
Summary
This clinical trial tested a new oral drug called GFH925 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study aimed to find a safe dose and see if the drug could shrink tumors in cancers like non-small cell lung cancer and colorectal cancer. It involved 334 adult participants whose cancer had progressed despite prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.